Tocilizumab vs Azathioprine in Neuromyelitis Optica Spectrum Disorders (TANGO)
Safety and Efficacy of Tocilizumab Versus Azathioprine in Neuromyelitis Optica Spectrum Disorders: a Randomized, Controlled, Open-label, Phase 2 Trial
Sponsor: Tianjin Medical University General Hospital
Listed as NCT03350633, this PHASE2/PHASE3 trial focuses on Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorders and remains completed. Sponsored by Tianjin Medical University General Hospital, it has been updated 8 times since 2017, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2/PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2/PHASE3
Phase: PHASE2_PHASE3 → PHASE2/PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE2_PHASE3
-
Nov 2019 — Jan 2021 [monthly]
Completed PHASE2_PHASE3
Status: Active Not Recruiting → Completed
-
Nov 2018 — Nov 2019 [monthly]
Active Not Recruiting PHASE2_PHASE3
▶ Show 3 earlier versions
-
Sep 2018 — Nov 2018 [monthly]
Active Not Recruiting PHASE2_PHASE3
Status: Recruiting → Active Not Recruiting
-
Jun 2018 — Sep 2018 [monthly]
Recruiting PHASE2_PHASE3
-
Dec 2017 — Jun 2018 [monthly]
Recruiting PHASE2_PHASE3
First recorded
Nov 2017
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Tianjin Medical University General Hospital
For direct contact, visit the study record on ClinicalTrials.gov .